FDA 505(b)(2) Breakthroughs: Sun Pharma Depot, Baxter RTU, and Landmark Norwich v. Kennedy Exclusivity Ruling
Summary of the blog post: 2-minute read.
API & IP Intelligence Roundup (07 September 2026)
The latest regulatory intelligence highlights vital lifecycle formulation innovations via the USFDA 505(b)(2) pathway, strategic corporate realignments, and a precedential D.C. Circuit ruling overturning FDA's interpretation of 180-day generic exclusivity forfeiture
1. Recent 505(b)(2) NDA Approvals & Filings (August 2026)
The 505(b)(2) pathway continues to deliver differentiated clinical value, de-risking development by building on established reference molecules
Baxter Healthcare (Sodium Bicarbonate Injection, USP — NDA 218524): Approved in ready-to-administer (RTA) Viaflo plastic containers (150 mEq/1,000mL)
. This factory-standardised, isotonic continuous-infusion presentation eliminates manual cleanroom compounding from hypertonic 8.4% vials under USP <797>, reducing the risk of bedside calculation errors and acute hypernatremia in intensive care units . Sun Pharma (Vobrig / Leuprolide Acetate Depot — NDA 213225): Cleared for advanced prostate cancer and endometriosis
. Bypassing rigid ANDA bioequivalence hurdle criteria for complex microspheres, Sun engineered an optimised depot injection with smaller needle gauges, room-temperature shelf stability, and continuous testosterone suppression below castration thresholds (20 ng/dL) . Seasons Biotechnology (Sehippy / Vortioxetine — NDA 218328): Granted tentative approval referencing Trintellix (1.2 Bn–$1.4 Bn market)
. Launch is positioned for early 2027 following the expiration of pediatric exclusivity in December 2026 . Gilead Sciences (Bixlenvo — NDA 221104): Approved as a complete single-tablet switch regimen combining bictegravir (75 mg) and lenacapavir (50 mg) for virologically suppressed HIV-1 adult patients
.
2. Corporate Strategies & Market Access
Astellas Affordable Access Agreement: Reached terms with the US government to lower Medicaid drug pricing and align future innovative therapies with international reference standards
. - India Glycols Demerger Blueprint: Demerged biopharma arm Ennature Bio Pharma targets ₹130–₹150 crore EBITDA, aiming to launch one new API annually while expanding into specialised, high-margin dietary fibres (guar gum derivatives).
3. IP Benchmark: Norwich v. Kennedy Overturns FDA on Generic Exclusivity
In Norwich Pharmaceuticals, Inc. v. Kennedy (D.C. Cir. No. 25-5137), the D.C. Circuit delivered a landmark decision regarding generic rifaximin (Xifaxan 550mg)
Failure to Market (§ 355(j)(5)(D)(i)(I)): Affirmed that 180-day exclusivity is single and indivisible
. First-filer Actavis did not forfeit exclusivity merely because Norwich carved out the hepatic encephalopathy (HE) indication . Strict But-For Causation (§ 355(j)(5)(D)(i)(IV)): Overturned FDA’s lenient "partial cause" standard for missing the 30-month tentative approval window
. A sponsor can only excuse missed deadlines if an FDA guidance change was the strict but-for cause of the delay . Commercial Impact: If the FDA finds on remand that Actavis had independent application flaws, Actavis will forfeit exclusivity, clearing Norwich's generic rifaximin for immediate approval years ahead of the 2028 settlement date
.
Contents
Recent 505 (b) (2) filings
General information
Astellas Pharma signs agreement with US government to support affordable access to medicines
India Glycols Plans To Launch One New API Each Year And Expand Dietary Fibre
Intellectual Property
Norwich Pharmaceuticals, Inc. v. Kennedy (D.C. Cir. No. 25-5137)
Recent 505 (b) (2) filings
General information
Astellas Pharma signs agreement with US government to support affordable access to medicines
India Glycols Plans To Launch One New API Each Year And Expand Dietary Fibre
- India Glycols has outlined a structured expansion blueprint for its newly demerged biopharma business, Ennature Bio Pharma Limited. The strategy focuses on launching one new Active Pharmaceutical Ingredient (API) annually while moving aggressively into the high-margin dietary fibre segment. Additionally, the company is intensifying operations to defend and grow its global footprint in Thiocolchicoside and specialized Nicotine derivatives.
- Data Snapshot
- The demerged biopharma business, Ennature Bio Pharma, targets an EBITDA of ₹130 crore to ₹150 crore over the next four to five years.
- Under the demerger scheme, India Glycols shareholders receive one equity share of Ennature Bio Pharma for every three shares held, and one share of IGL Spirits for every one share held.
- The dietary fibre expansion will leverage a specialized Guar Gum sub-segment that is projected by CARE Ratings to contribute ₹65 crore to ₹70 crore in revenue at high operating margins of 25% to 30%.
Intellectual Property
Norwich Pharmaceuticals, Inc. v. Kennedy (D.C. Cir. No. 25-5137)
- The Product & Reference Listed Drug (RLD): Rifaximin 550 mg (marketed as Xifaxan by Salix Pharmaceuticals) is approved for irritable bowel syndrome with diarrhoea (IBS-D) and hepatic encephalopathy (HE).
- First-to-File (Actavis/Teva): Actavis filed the first substantially complete ANDA containing Paragraph IV certifications to Salix's compound, IBS-D, and HE patents on 18 December 2015, qualifying for 180-day marketing exclusivity. Actavis settled Hatch-Waxman patent litigation in 2018, obtaining a license to enter the market no earlier than 1 January 2028.
- Subsequent Applicant (Norwich): Norwich filed generic rifaximin ANDAs. In Delaware patent litigation, the IBS-D patent was invalidated, while the HE patent was held valid and infringed. Norwich amended its ANDA to include Paragraph IV certifications for the compound and IBS-D patents while carving out the HE indication via a section viii statement.
- The FDA Decision: In January 2025, the FDA tentatively approved Norwich's ANDA, finding that Actavis’s unexpired exclusivity blocked final approval. The FDA rejected Norwich’s claims that Actavis forfeited its exclusivity under the "failure to market" or "failure to obtain tentative approval" provisions.
- Statutory Framework: Forfeiture occurs only after court decisions or settlement orders finding non-infringement or invalidity in each patent qualify the first applicant for exclusivity.
- Rejection of "Relational / Partial" Forfeiture: Norwich argued for a "matching certifications" theory, contending Actavis forfeited exclusivity because triggering events occurred for all patents shared between the applications (IBS-D), despite no triggering event occurring for the HE patent (which Norwich carved out).
- The Holding: The Court rejected Norwich's interpretation, holding that 180-day exclusivity is a single, indivisible statutory benefit. A first applicant forfeits exclusivity as to all subsequent filers or none at all. Because Actavis maintained a valid Paragraph IV certification to the HE patent for which no court trigger had occurred, Actavis did not forfeit exclusivity under the failure-to-market provision.
- The Statutory Exception: A first applicant forfeits exclusivity if it fails to obtain tentative approval within 30 months of filing, unless the failure is "caused by a change in or a review of the requirements for approval" imposed by the FDA after filing.
- The FDA's Flawed Standard: Actavis missed its 30-month deadline in June 2018. The FDA excused the failure, saying its March 2017 draft product-specific dissolution guidance was "one of the causes" of the delay, rejecting a strict "but-for" standard.
- The Holding (Strict But-For Causation): The Court ruled that the phrase "caused by" in the law means strict "but-for" causation. In simple terms:
- The first generic applicant can avoid losing its 180-day exclusivity only if it proves that it would have received timely tentative approval within 30 months if the FDA had not changed its rules.
- An FDA guidance change is not enough if it is only one of several reasons for the delay. If the generic company had other flaws in its application that would have prevented approval on their own, the company cannot use the FDA's rule change as an excuse to keep its monopoly.
- It agreed that Actavis did not lose its exclusivity under the "failure to market" rule.
- It disagreed with the FDA's lenient standard on the 30-month approval delay.
- The Court sent the case back (remanded) to the FDA to re-examine Actavis’s application using the strict "but-for" standard to determine whether Actavis officially forfeited its 180-day exclusivity.
- Potential Immediate Launch for Norwich: If the FDA finds on remand that Actavis had other independent flaws in its ANDA that would have caused it to miss the 30-month deadline anyway, Actavis will forfeit its 180-day exclusivity. This would clear the path for the FDA to grant immediate final approval to Norwich’s 550 mg generic rifaximin (for the IBS-D indication), breaking Salix and Teva’s market monopoly years ahead of the agreed 2028 settlement date.
- Closing a Major Loophole in Hatch-Waxman Exclusivity: First-to-file generic companies often rely on routine FDA guidance revisions to excuse long application delays, creating a bottleneck that blocks subsequent generics from entering the market. This ruling closes that loophole by holding first filers to a strict standard: if their drug application was fundamentally deficient or delayed on its own merits, they cannot rely on minor regulatory changes to hoard 180-day exclusivity.
